A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation

Trial Profile

A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Bronchiolitis obliterans
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Apr 2016 Results (n=22) presented at the 36th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 02 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top